MYCELEX by Bayer is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. First approved in 1979.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
MYCELEX (clotrimazole) is a broad-spectrum antifungal agent used to treat oral candidiasis (thrush) by altering fungal cell membrane permeability. The drug exhibits fungistatic activity at lower concentrations and fungicidal activity against Candida species at higher concentrations. It is formulated as an oral solution/troche with prolonged salivary persistence enabling convenient dosing intervals.
As a mature, LOE-approaching product, MYCELEX is transitioning out of peak revenue; brand team likely focused on market maintenance and managed decline strategies.
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal in vitro against Candida…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on MYCELEX at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Working on MYCELEX offers limited career growth; the product is approaching LOE with no linked job openings and faces mature market consolidation. Roles are primarily defensive (market maintenance, generic response) rather than building new franchises or launching innovations.